selegiline / Generic mfg. - LARVOL DELTA

Hyaluronic acid-based selegiline nanostructured lipid carriers incorporated dissolving microneedles: A localised transdermal delivery strategy for obesity management. (PubMed, Colloids Surf B Biointerfaces) - "In vivo studies conducted on 7 groups of Wistar rats revealed that the optimised formulation showed a substantial decrease in body weight, abdominal circumference, triglycerides, and low-density lipoprotein (LDL) levels, with no skin irritation. This emphasises the ability of SEL- NLCs loaded HA-based DMNs as a potent drug delivery system, elevating SEL's anti- obesity activity for the improved management of obesity."

Journal • Dyslipidemia • Genetic Disorders • Obesity

Selegiline induces neuroprotection via PGC-1α/Nrf2 gene upregulation in H2O2 -treated hippocampal-derived neural stem/progenitor cells. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "These findings suggest that selegiline mitigates oxidative stress-induced cytotoxicity by activating Nrf2/PGC-1α signaling and promoting anti-apoptotic gene expression, thereby preserving mitochondrial function and enhancing cell survival. Overall, selegiline may represent a promising therapeutic agent for protecting neural progenitor cells and alleviating neuronal damage in neurodegenerative disorders."

IO biomarker • Journal • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Huntington's Disease • Movement Disorders • Multiple Sclerosis • Parkinson's Disease • BCL2 • NFE2L2

Topical selegiline accelerates cutaneous wound healing with phase-specific modulation of MAPK signaling. (PubMed, Inflammopharmacology) - "Topical selegiline was associated with faster excisional wound repair, most consistently at 1-2%, by accelerating closure and coordinating inflammatory resolution, growth-factor recovery, apoptosis balance, and MAPK-related signaling across healing phases. These findings support further preclinical evaluation of topical selegiline, including mechanistic validation, local and systemic safety assessment, pharmacokinetic characterization, and investigation in impaired or chronic wound models."

Journal • Inflammation • Oncology • IL1B • IL6 • MAPK8 • TGFB1 • TNFA

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease. (PubMed, Ann Med) - "However, at its current pricing, rasagiline is not cost-effective. Significant price reductions or definitive proof of long-term superiority are required to justify its economic value."

Clinical • HEOR • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Reproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease. (PubMed, J Med Cases) - "The phenomenon was subsequently reproduced during supervised medication rechallenge, but did not occur during monotherapy or combination therapy with dopamine agonists (pramipexole, rotigotine, and bromocriptine) and selegiline. The described phenomenon may represent a rare or underrecognized adverse effect of levodopa. As a part of comprehensive follow-up on patient's health and wellbeing after treatment for PD, careful attention to emergent unusual thermal phenomena can constitute good clinical practice."

Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Satellite Glial Cells Synthesize and Release GABA to Activate Extrasynaptic GABAA Receptors That Modulate Dorsal Root Ganglia Neuron Excitability. (PubMed, Glia) - "Likewise, the use of selegiline and CaCCinh on cAP occluded the effects of picrotoxin. These results support that GABA synthesized and released by satellite glial cells activates extrasynaptic GABAA receptors, thereby modulating the excitability of sensory neurons."

Journal

Zembrin® Mitigates Reserpine-Induced Motor Dysfunction and Oxidative Stress in Parkinson's Disease: In Vivo and In Silico Analyses. (PubMed, Molecules) - "Zebrafish larvae were subjected to pre-treatment with reserpine, followed by exposure to Zembrin®, with selegiline and L-dopa as positive controls...Reserpine induced hypolocomotion and oxidative stress in zebrafish larvae, and Zembrin® (12.5 µg/mL) effectively enhanced locomotion and reduced oxidative stress. The molecular docking, molecular dynamics simulations, and binding free energy calculations revealed that four mesembrine alkaloids (mesembranol, mesembrenol, mesembrenone, and mesembrine) form stable and energetically favourable complexes with monoamine oxidase B (MAO-B) and dopamine transporter (DAT), which are significant targets for addressing both the motor and non-motor effects of PD."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Discovery of a Potent and Selective MAO-B Inhibitor From a Donepezil-Linked Chalcone Library With Promising Antiparkinsonian Activity. (PubMed, Drug Dev Res) - "A focused library of 19 donepezil-linked chalcones (DLCs) was efficiently synthesised through microwave-assisted Claisen-Schmidt condensation and subsequently profiled for their inhibitory activities against cholinesterases (AChE and BuChE) as well as monoamine oxidases (MAO-A and MAO-B). Notably, DLC14 consistently outperformed DLC6 and demonstrated an efficacy profile comparable to that of Selegiline, highlighting its therapeutic potential as an antiparkinsonian agent. These results indicate that DLC14 is potent and selective MAO-B inhibitor and could serve as promising candidate for the treatment of neurodegenerative disorders, such as Parkinson's disease."

Journal • Alzheimer's Disease • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Diagnostic Reclassification From Parkinson's Disease to Multiple System Atrophy Based on Longitudinal Clinical and Imaging Findings: A Case Report. (PubMed, Cureus) - "Repeat MIBG scintigraphy performed after selegiline discontinuation revealed an improvement in the heart-to-mediastinum ratio, suggesting a possible drug-related effect on tracer uptake. This case illustrates the limitations of single-time-point diagnostic assessments and highlights the value of longitudinal, multimodal evaluation. It also suggests that MIBG abnormalities may be reversible, underscoring the need for cautious interpretation of MIBG findings in the differential diagnosis of PD and MSA."

Journal • CNS Disorders • Hypotension • Movement Disorders • Multiple System Atrophy • Parkinson's Disease

Design-Expert Assisted Formulation Development, Optimization, and Evaluation of Selegiline and Biochanin A Loaded Self-Nanoemulsifying Drug Delivery System. (PubMed, Drug Dev Res) - "Notably, SNEDDS achieved higher brain Cmax values for SEL (5.6 ± 0.41 μg mL-1) and BCA (13.84 ± 1.14 μg mL-1), as well as elevated plasma concentrations of SEL (6.51 ± 0.43 μg mL-1) and BCA (762.65 ± 16.82 μg mL-1). Collectively, the results underscore the potential of the SEL-BCA SNEDDS as a combinational delivery platform that could improve the effectiveness of combination therapy for the management of PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

In-depth multimodal validation of 18F-THK5351 for imaging monoamine oxidase-B-mediated reactive astrogliosis in Alzheimer's and related neurodegenerative diseases. (PubMed, Exp Mol Med) - "In a patient with corticobasal syndrome, tracer signals decreased during selegiline treatment and reappeared after drug withdrawal, mirroring preclinical pharmacological responses. Collectively, these findings demonstrate that 18F-THK5351 uptake primarily reflects MAO-B-mediated reactive astrogliosis rather than tau pathology, providing mechanistic insight into its signal origin and underscoring the value of cross-scale, multimodal validation in PET tracer development for neurodegenerative disease research."

Journal • Alzheimer's Disease • CNS Disorders

Design, Synthesis, and Preliminary Evaluation of Fluorinated Indazole-5-carboxamide Derivatives for MAO-B PET Imaging. (PubMed, J Med Chem) - "Dynamic PET imaging revealed efficient blood-brain barrier penetration of [18F]32 (SUV1 min = 1.40 in rat), with specific binding confirmed by selegiline blocking...Metabolism studies showed that 62 ± 4% of brain radioactivity remained as the parent fraction at 30 min post-injection. Altogether, this work provides a novel MAO-B PET tracer based on an indazole carboxamide scaffold, potentially providing inspiration for future tracer development."

Journal • CNS Disorders

Chitosan Nanoparticles Co-Encapsulating Selegiline Analogue and L-Tyrosine Mitigate Depression-Related Pathology and Cognitive Decline in Rats. (PubMed, Biomolecules) - "Molecular docking studies showed that PAMTP had high affinity for monoamine oxidase and acetylcholinesterase, supporting its role as an MAO-B inhibitor and cholinergic modulator. These findings suggest that En@PAMTP_Tyr is a promising nanoplatform for targeting MAO-B in depression, addressing mood, cognitive function, oxidative stress, inflammation, and Alzheimer-like pathology in the hippocampus."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • BDNF • IL10 • TNFA

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation. (PubMed, Am J Ophthalmol) - "In this cohort study, levodopa ± carbidopa use was associated with lower 3-year risk of conversion to nAMD in two independent matched comparisons, whereas DRD2 agonists were not associated with significant differences in risk. These findings suggest dopaminergic signaling may influence AMD progression and warrant further prospective investigation."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • DRD2

Combination therapy of levodopa with safinamide is more effective than with rasagiline and zonisamide in Asian Parkinson's disease patients with motor fluctuations: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, J Neurol) - "The findings suggest that levodopa in combination with safinamide 100 mg is more efficacious than combinations with rasagiline 1 mg or zonisamide 25 mg for alleviating motor fluctuations and improving motor symptoms in Asian PD patients, and shows a more favourable (though not statistically significant) trend compared with zonisamide 50 mg."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials. (PubMed, JAMA Psychiatry) - "Cocaine and methamphetamine use disorders are major public health challenges with no approved pharmacological treatments...Tested pharmacotherapies included topiramate, bupropion, modafinil, ondansetron, tiagabine, cabergoline, reserpine, selegiline, and baclofen, each compared to placebo in double-blind trials...The present findings of this meta-analysis underscore the importance of evaluating a continuum of outcomes rather than focusing solely on abstinence in RCTs. The results suggest that reductions in stimulant use may serve as meaningful efficacy signals that could be underestimated when relying solely on stringent outcomes, such as abstinence."

Journal • Retrospective data

L-DOPA influences transferrin-dependent iron release at the blood-brain barrier. (PubMed, Fluids Barriers CNS) - "Selegiline, by contrast, produced delayed and modest effects and preserved transporter and ferritin expression across both apo- and holo-Tf conditions. These findings identify a previously unrecognized direct interaction between dopaminergic therapy and parenchymal transferrin signaling, positioning L-DOPA as a significant modulator of BBB iron export and revealing a mechanism through which PD treatments may negatively influence regional brain iron balance."

Journal • CNS Disorders • Hematological Disorders • Movement Disorders • Parkinson's Disease • FTL • TFRC

Wenshen Yanggan Decoction improves intestinal function in mouse models of Parkinson's disease by regulating intestinal bioactive substances (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "WSYG effectively improve motor deficits and intestinal dysfunction in PD mice possibly by up-regulating intestinal VIP/CCK and down-regulating DAO/D-LA/LPS expressions to reduce intestinal barrier permeability, thereby alleviating dopaminergic neuronal damage."

Journal • Preclinical • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease • OCLN • TJP1

Identification of a nanomolar, selective MAO-B inhibitor from piperidine-based chalcones with anti-Parkinson potential. (PubMed, Bioorg Chem) - "Notably, PBC21 exhibited efficacy comparable to the reference drug selegiline in several parameters, highlighting its potential as a promising antiparkinsonian lead candidate...Based on the results obtained, it is proposed that PBC21 is a potent and selective MAO-B inhibitor. These findings position PBC21 as a promising lead compound in the treatment of neurodegenerative diseases such as Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Herbs Nutrients and More for Disorders of Mood Anxiety Trauma Cognitive Function ADHD and Sexual Function (APA 2026) - "They will also briefly review B Vitamins, methylfolate, L-theanine, S-adenosylmethionine (SAMe), N-acetyl cysteine, omega-3 fatty acids (fish oils), Hokkaido Scallop Oil, melatonin, centrophenoxine, CDP-choline, racetams, vinpocetine, cilostazol, selegiline, and LUMA TC (medical food formula), and Maca (Lepidium meyenii), marapuama (Ptychopetalum olacoides). Objective Four: Discuss herbs and nutrients that can be integrated into the treatment of depression to improve patient outcomes. Objective Five: Evaluate the clinical relevance of information about potential herb-drub interactions.; Objective One: Identify herbs and nutrients that can be integrated into the treatment of anxiety disorders and PTSD to imrove patient outcomes.; Objective Two: List 1 herb and 2 nutrients that can enhance brain function for individuals being treated for cognitive impairment due to traumatic brain injury, stroke, or dementia.; Objective Three: Access information and tools to develop skills..."

ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Depression • Post-traumatic Stress Disorder • Psychiatry • Vascular Neurology

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors. (PubMed, J Neural Transm (Vienna)) - "All ADD-ON therapies showed comparable treatment stability and tolerability. No statistically significant sex-related differences were observed, although a trend toward more frequent therapy modifications was found in female patients."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Integrative multi-omics analysis identifies key ubiquitination regulators in prostate cancer. (PubMed, Transl Oncol) - "POLI and TRIM8 are key ubiquitination regulators with causal links to PCa pathogenesis, exhibiting distinct expression patterns correlated with tumor aggressiveness. Functional validation confirms TRIM8 as a tumor suppressor in PCa. These genes represent promising therapeutic targets, and the predicted interaction with selegiline hydrochloride highlights a potential drug-repurposing strategy."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Targeted Protein Degradation • POLI

Selegiline, a monoamine oxidase-B inhibitor as a modulator of metabolic reprogramming for cancer therapy: a review. (PubMed, Front Pharmacol) - "Additionally, combination approaches with chemotherapeutics, metabolic inhibitors, and immunotherapies show synergistic potential. This review summarizes current insights into selegiline's role in metabolic reprogramming, highlights existing challenges, and discusses future opportunities for repositioning selegiline as a targeted metabolic modulator in cancer therapy."

Journal • Review • CNS Disorders • Metabolic Disorders • Oncology

The Safety and Efficacy of Monoamine Oxidase-B Inhibitors as Add-on Therapy to Dopamine Agonists for the Treatment of Parkinson’s Disease: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Background Parkinson's disease (PD) is a neurodegenerative disease, treated with carbidopa/levodopa or a dopamine agonist...They can be irreversible (selegiline and rasagiline) or reversible (safinamide)...Conclusions Selegiline (10mg/day) and safinamide (100mg) offer good therapeutic benefit as add-on therapy for PD. However, safinamide (100mg) has a relatively better safety profile as compared to selegiline (10mg/day). Further research should emphasize on long-term effects of these drugs through longitudinal studies focusing on patient-reported outcomes."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Microneedle assisted drug delivery of liposome loaded with selegiline hydrochloride for effective management of Parkinson's disease intervention. (PubMed, J Liposome Res) - "A histopathological study showed improved neuronal regeneration for the SH-LP3-MNP formulation. Through these findings, it was reported that the SH-LP3-MNP formulation is a promising approach for delivering liposomes loaded with selegiline through the skin for the treatment of Parkinson's disease symptoms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease